Roche ‘steps up’ for gene therapy with $4.3 bn Spark bet
Swiss-based pharma company buying spark as rivals move aggressively into gene therapy
More firms weigh IPOs as biotech fever reaches Europe
Top candidates for a share sale include Swiss firms AC Immune and Molecular Partners
Bubble fears grow amid glut of IPOs in the US by early-stage biotechs
Dicerna Pharmaceuticals a focal point of concern as it has yet to enter clinical trials and refused to impose share sale block on major shareholders
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Stardust
Inquests into the nightclub fire that led to the deaths of 48 people
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices